



TECH CENTER 1600/2900

DEC 04 2001

RECEIVED

SUBMISSION UNDER MPEP 609 D Page 1 of 4	Application Number	09/921,516
	Filing Date	1 August 2001
	First Named Inventor	ITRI, Loretta
	Group Art Unit	N/A
	Examiner Name	N/A
	Attorney Docket Number	ORT-1462

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	U.S. Patent Document		Pages, Columns, Lines, where relevant passages or relevant figures appear
			Number	Kind Code ² (if known)	


FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	Foreign Patent Document			Pages, Columns, Lines, where relevant passages or relevant figures appear	T ³
			Office ³	Number ⁴	Kind Code ⁵		
KAC		ORTHO-MCNEIL PHARMACEUTICAL, INC.		WO 00/67769			
		ORTHO-MCNEIL PHARMACEUTICAL, INC.		WO 00/67776			
		ORTHO-MCNEIL PHARMACEUTICAL, INC.		WO 00/61169			
		KORKUT, Edib		WO 00/38705			
		PERRINE et al.		WO 98/04290			
		ELI LILLY AND COMPANY		WO 00/32772			
		SCHERING CORPORATION		WO 97/16204			
		BRIGHAM AND WOMEN'S HOSPITAL		WO 92/08493			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
KAC		✓ Abrams et al., "Epoetin alfa Improves the Quality of Life (QoL) in HIV+ Patients with Anemia", <i>Blood</i> ; (1998) 92(Sup. 1, Pt. 2):10b (Abs 3020); 40 th Annual Meeting of the American Society of Hematology, Miami Beach, FL (Dec. 4-8, 1998).	
		✓ Blanchard et al., "Regulation of the Erythropoietin Gene", <i>Stem Cells</i> (1993) 11(1):1-7.	
		✓ Brugnara et al., "Effects of Subcutaneous Recombinant Human Erythropoietin in Normal Subjects: Development of Decreased Reticulocyte Hemoglobin Content and Iron-Deficient Erythropoiesis", <i>J. Lab. Clin. Med.</i> (1994) 123(5):660-667.	
		✓ David F. Cella, "The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: A New Tool for the Assessment of Outcomes in Cancer Anemia and Fatigue", <i>Seminars in Hematology</i> (1997, July) 34(3, Sup. 2):13-19.	
		✓ David F. Cella, "F.A.C.T. Manual: Functional Assessment of Cancer Therapy (FACT) Scales and the Functional Assessment of HIV Infection (FAHI) Scale Version 3" (September 1, 1994) (prepared with Amy E. Bonomi) Rush-Presbyterian-St. Lukes Medical Center, Chicago, Illinois.	
		✓ Cheung et al., "Comparative Pharmacokinetics, Safety, and Tolerability after Subcutaneous Administration of Recombinant Human Erythropoietin Formulated with Different Stabilizers", <i>Biopharm. Drug Dispos.</i> (2000) 21(6):211-219.	
		✓ Cheung et al., "Pharmacokinetics and Pharmacodynamics of Recombinant Human Erythropoietin After Single and Multiple Subcutaneous Doses to Healthy Subjects", <i>Clinical Pharmacology & Therapeutics</i> (1998) 64(4):412-423.	

Examiner Signature	<i>Harmon G. Carulla</i>	Date Considered	9/19/04
-----------------------	--------------------------	--------------------	---------



SUBMISSION UNDER MPEP 609 D

Page 2 of 4

Application Number	09/921,516
Filing Date	1 August 2001
First Named Inventor	ITRI, Loretta

TECHCENTER 1600/2900

DEC 04 2001

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T*
RA-C		✓ <u>Damon</u> et al., "High-Dose Chemotherapy and Hematopoietic Stem Cell Rescue for Breast Cancer: Experience in California", <i>Biology of Blood and Marrow Transplantation</i> (2000) 6(5):496-505.	
		✓ <u>Danna</u> et al., "Erythropoietin Therapy for the Anemia Associated with AIDS and AIDS Therapy and Cancer", <i>Erythropoietin in Clinical Applications: An International Perspective</i> (Marc B. Garnick, Ed.; Marcel Dekker, Pub.) Jan. 1990, Ch. 11, 301-324.	
		✓ <u>Davis</u> et al., "Interferon alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C", <i>New England Journal of Medicine</i> (1998) 339(21):1493-1499.	
		✓ <u>Davis</u> et al., "Retreatment of Relapse After Interferon Therapy for Chronic Hepatitis C: An International Randomized Controlled Trial of Interferon Plus Ribavirin vs. Interferon Alone", <i>Hepatology</i> (1997) 26(4):247A (Abstract only).	
		✓ <u>de Andrade</u> et al., "Baseline Hemoglobin as a Predictor of Risk of Transfusion and Response to Epoetin alfa in Orthopedic Surgery Patients", <i>American Journal of Orthopedics</i> (Aug. 1996) 25(8):533-542.	
		✓ <u>George D. Demetri</u> , "Evidence-Based Use of Hematopoietic Cytokines in Clinical Oncology", <i>Clinical Applications of Cytokines and Growth Factors</i> , Vol. 80, (J. R. Wingard, Ed.; Kluwer Academic Publishers), Jan. 1999, Ch. 6, 137-149.	
		✓ <u>Demetri</u> et al., "Quality of Life Benefit in Chemotherapy Patients Treated with Epoetin alfa is Independent of Disease Response or Tumor Type: Results from a Prospective Community Oncology Study", <i>J. Clin. Oncol.</i> (1998) 16(10):3412-3425.	
		✓ <u>Dieterich</u> et al., "Interferon- α (IFN- α) and Ribavirin (RBV) Therapy for Hepatitis C (HCV) in HIV Co-Infected Patients", (Abstract and Poster Presentation for American Society for Microbiology) <i>Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy</i> , (26-29 Sep. 1999) San Francisco, CA.	
		✓ <u>Donahue</u> et al., "Suppression of <i>In Vitro</i> Haematopoiesis Following Human Immunodeficiency Virus Infection", <i>Nature (London)</i> (1987, Mar.) 326(6109):200-203.	
		✓ <u>Dusheiko</u> et al., "Ribavirin Treatment for Patients with Chronic Hepatitis C: Results of a Placebo-Controlled Study", <i>J. Hepatol.</i> (1996) 25(5):591-598.	
		✓ <u>Escribano</u> et al., "Expression of the c-kit (CD117) Molecule in Normal and Malignant Hematopoiesis", <i>Leukemia and Lymphoma</i> (1998) 30(5/6):459-466.	
		✓ <u>Fiel</u> et al., "Increased Hepatic Iron Deposition Resulting from Treatment of Chronic Hepatitis C with Ribavirin", <i>Am. J. Clin. Pathol.</i> (2000) 113(1):35-39.	
		✓ <u>Galson</u> et al., "Cis Elements that Regulate the Erythropoietin Gene", <i>Ann. N. Y. Acad. Sci.</i> (1994) 718:21-30.	
		✓ <u>D. Gillings and G. Koch</u> , "The Application of the Principle of Intention-to-Treat in the Analysis of Clinical Trials", <i>Drug Information Journal</i> (1991) 25:411-424.	
		✓ <u>John Glaspy</u> , "The Impact of Epoetin alfa on Quality of Life During Cancer Chemotherapy: A Fresh Look at an Old Problem", <i>Seminars in Hematology</i> (1997, July) 34(3 Sup. 2):20-26.	
		✓ <u>Glaspy</u> et al., "Impact of Therapy with Epoetin alfa on Clinical Outcomes in Patients with Non-Myeloid Malignancies during Cancer Chemotherapy in Community Oncology Practice", <i>J. Clin. Oncol.</i> (1997, March) 15(3):1218-1234.	
		✓ <u>Mark A. Goldberg</u> , "Perioperative Epoetin alfa Increases Red Blood Cell Mass and Reduces Exposure to Transfusions: Results of Randomized Clinical Trials", <i>Semin. Hematol.</i> (1997, July) 34(3 Sup. 2):41-47.	
		✓ <u>Goldberg</u> et al., "A Safety and Efficacy Comparison Study of Two Dosing Regimens of Epoetin Alfa in Patients Undergoing Major Orthopedic Surgery", <i>The American Journal of Orthopedics</i> (1996, August) 544-552.	
		✓ <u>Jerome E. Groopman and Loretta M. Itri</u> , "Chemotherapy-Induced Anemia in Adults: Incidence and Treatment", <i>J. Natl. Cancer Inst.</i> (1999, October) 91(19):1616-1634.	

Examiner Signature	<i>John H. Canella</i>	Date Considered	9/19/04
--------------------	------------------------	-----------------	---------

RECEIVED

DEC 04 2001

TECH CENTER 1600/2900




SUBMISSION UNDER MPEP 609 D		Application Number	09/921,516
Page 3 of 4		Filing Date	1 August 2001
		First Named Inventor	ITRI, Loretta

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
KAR	✓	Groopman et al., "Hematopoietic Growth Factors in AIDS", <i>Seminars in Oncology</i> (1992, August) 19(4):408-414.	
	✓	J.E. Groopman, "Antiretroviral Therapy and Immunomodulators in Patients with AIDS", <i>American Journal of Medicine</i> (April, 1991) 90(4A):185-215.	
	✓	Jerome E. Groopman, "Retroviral Infection and Hemopoiesis", <i>Molecular Control of Haemopoiesis</i> , Vol. 148, (G. Bock and J. Marsh: Eds.; John Wiley & Sons, Ltd., Chichester, United Kingdom: Pub.) Ciba Foundation Symposium, May 2-4, 1989, London, United Kingdom (1990, Jan) 148:173-185.	
	✓	Groopman et al., "Hematopoietic Growth Factors: Biology and Clinical Applications", <i>N. Engl. J. Med.</i> (1989) 321(21):1449-1459.	
	✓	David H. Henry, "Supplemental Iron: A Key to Optimizing the Response of Cancer-Related Anemia to rHuEPO?", <i>Oncologist</i> (1998) 3(4):275-278.	
	✓	David H. Henry, "Epoetin alfa and High-Dose Chemotherapy", <i>Seminars in Oncology</i> (1998, June) 25(3, Sup. 7):54-57.	
	✓	David H. Henry, "Experience with Epoetin alfa and Acquired Immunodeficiency Syndrome Anemia", <i>Seminars in Oncology</i> (1998, June) 25(3, Sup. 7):64-68.	
	✓	Henry et al., "Recombinant Human Erythropoietin in the Treatment of Anemia Associated with Human Immunodeficiency Virus (HIV) Infection and Zidovudine Therapy", <i>Annals of Internal Medicine</i> (1992, November) 117(9):739-748.	
	✓	Laso et al., "Alterations in Tumor Necrosis Factor- α , Interferon- γ , and Interleukin-6 Production by Natural Killer Cell-Enriched Peripheral Blood Mononuclear Cells in Chronic Alcoholism: Relationship with Liver Disease and Ethanol Intake", <i>Alcohol.: Clin. Exp. Res.</i> (1997) 21(7):1226-1231.	
	✓	McHutchinson et al., "Interferon alfa-2-b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis as Initial Treatment for Chronic Hepatitis", <i>New England Journal of Medicine</i> (1998, November) 339(21):1485-92.	
	✓	R. T. Means and S. B. Krantz, "Inhibition of Human Erythroid Colony-Forming Units by γ -Interferon Can Be Corrected by Recombinant Human Erythropoietin", <i>Blood</i> (1991, November) 78(10):1564-2567.	
	✓	Molina et al., "Human Immunodeficiency Virus Does Not Induce Interleukin-1, Interleukin-6, or Tumor Necrosis Factor in Mononuclear Cells", <i>J. Virology</i> (1990, June) 64(6):2901-2906.	
	✓	Pecherstorfer et al., "Erythropoietin in Multiple Myeloma", <i>Deutsche Medizinische Wochenschrift</i> (July, 1990) 115(28-29):1096-1099. (translated)	
	✓	David L. Porter and Mark A. Goldberg, "Regulation of Erythropoietin Production", <i>Exp. Hematol.</i> (Charlottesville, VA) (1993) 21(3):399-404.	
	✓	Reichard et al., "Randomized Double-Blind, Placebo-Controlled Trial of Interferon α -2b with and without Ribavirin for Chronic Hepatitis C", <i>Lancet</i> (1998, Jan.) 351:83-87.	
	✓	Reichard et al., "Therapy of Hepatitis C: Alpha Interferon and Ribavirin", <i>Hepatology</i> (1997, September) 26(3 Sup. 1):108S-111S.	
	✓	Revicki et al., "Recombinant Human Erythropoietin and Health-Related Quality of Life of AIDS Patients with Anemia", <i>J. Acq. Immune. Defic. Syn.</i> (1994) 7(5):474-484.	
	✓	San Miguel et al., "Treatment of Multiple Myeloma", <i>Hematologica</i> (1999) 84(1):36-58.	
	✓	Schalm et al., "Ribavirin Enhances the Efficacy but not the Adverse Effects of Interferon in Chronic Hepatitis C", <i>J. Hepatol.</i> (1997) 26(5):961-966.	
	✓	Schvarcz et al., "Combination Treatment with Interferon alfa-2b and Ribavirin for Chronic Hepatitis C in Patients Who Have Failed to Achieve Sustained Response to Interferon Alone: Swedish Experience", <i>J. Hepatol.</i> (1995) 23(Sup. 2):17-21.	

Examiner Signature	<i>John G. Canale</i>	Date Considered	9/19/04
--------------------	-----------------------	-----------------	---------



SUBMISSION UNDER MPEP 609 D

Page 4 of 4

Application Number	09/921,516
Filing Date	1 August 2001
First Named Inventor	ITRI, Loretta

TECH CENTER 1600/2900

DEC 04 2001

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T2
KAC	✓	Silvestris et al., "Immunomodulation of T and B Cell Functions in Multiple Myeloma Patients Treated with Combined Erythropoietin and α -Interferon Therapy", <i>International Journal of Clinical and Laboratory Research</i> (1995) 25(2):79-83.	
	✓	Stowell et al., "An Open-Label, Randomized Study to Compare the Safety and Efficacy of Perioperative Epoetin alfa with Preoperative Autologous Blood Donation in Total Joint Arthroplasty", <i>Orthopedics</i> (Jan. 1999) 22(1, Supp.):s105-s112.	
	✓	Svensson et al., "Determination of Ribavirin in Serum Using Highly Selective Solid-Phase Extraction and High-Performance Liquid Chromatography", <i>Therapeutic Drug Monitoring</i> (2000) 22(2): 215-218.	
	✓	Karen Weiss, "Safety Profile of Interferon- γ Therapy", <i>Semin. Oncol.</i> (1998, February) 25(1 Sup. 1):9-13.	
	✓	Weisz et al., "Erythropoietin Use for Ribavirin/Interferon Induced Anemia in Patients with Hepatitis C", (Abstract and Poster Presentation) 38 th Interscience Conference on Antimicrobial Agents and Chemotherapy, (24-27 Sep. 1998) San Diego, CA.	

Examiner Signature	<i>John A. Gaudin</i>	Date Considered	9/14/01
--------------------	-----------------------	-----------------	---------



SUBMISSION UNDER MPEP 609 D

Page 1 of 2

Application Number	09/921,516
Filing Date	1 August 2001
First Named Inventor	ITRI, Loretta
Group Art Unit	N/A
Examiner Name	N/A
Attorney Docket Number	ORT-1462

TECH CENTER 1600/2800

RECEIVED
FEB 05 2002

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	U.S. Patent Document		Pages, Columns, Lines, where relevant passages or relevant figures appear
			Number	Kind Code ² (if known)	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	Foreign Patent Document			Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
			Office ³	Number ⁴	Kind Code ⁵		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
KAL		Aviles et al., "Treatment of Refractory Low Grade Lymphoma with Chlorambucil Alternating with Interferon and Radiotherapy", <i>Cancer Biother.</i> (1995) 10(4):273-277.	
		Akpek et al., "Chemotherapy with Etoposide, Vincristine, Doxorubicin, Bolus Cyclophosphamide, and Oral Prednisone in patients with refractory cutaneous T-Cell Lymphoma" <i>Cancer</i> (1999) 86(7):11368-1376.	
		Bajorin et al., "Ifosfamide, Paclitaxel, and Cisplatin for Patients with Advanced Transitional Cell Carcinoma of the Urothelial Tract", <i>Cancer</i> (2000) 88(7):1671-1678.	
		Bourantas et al., "Combination Therapy with Recombinant Human Erythropoietin, Interferon-alpha-2b and Granulocyte-Macrophage Colony Stimulating Factor in Idiopathic Myelofibrosis", <i>Acta Haematol.</i> (1996) 96(2):79-82.	
		Cortes et al., "Result of Interferon-Alpha Therapy in Patients with Chronic Myelogenous Leukemia 60 Years of Age and Older", <i>Amer. J. Medicine</i> (1996) 100(4):452-455.	
		Hilbe et al., "Cladribine Treatment of a Patient with Hairy Cell Leukemia and Concomitant Multiple Sclerosis", <i>Acta Haematol.</i> (1999) 102(2):99-100.	
		Hinotsu et al., "Intravesical Chemotherapy for Maximum Prophylaxis of New Early Phase Superficial Bladder Carcinoma Treated by Transurethral Resection: A Combined Analysis of Trials by the Japanese Urological Cancer Research Group using Smoothed Hazard Function", <i>Cancer</i> (1999) 86(9):1818-1826.	
		McPherson et al., "Suppression of Hepatitis C Virus in Human Immunodeficiency Virus Iron-Loading Anemia (HCV-HIV-ILA) Patients with HAART and Recombinant Human Erythropoietin (r-HuEPO)", (2000) 96(11, Part 2):7B.	
		Naglieri et al., "Standard Interleukin-2 (IL-2) and Interferon-alpha Immuno-therapy Versus an IL-2 and 4-Epirubicin Immuno-Chemotherapeutic Association in Metastatic Renal Cell Carcinoma", <i>Anticancer Res.</i> (1998) 3B:2021-2026.	

Examiner Signature	<i>Norm P. Gaudin</i>	Date Considered	9/14/2004
--------------------	-----------------------	-----------------	-----------

RECEIVED

FEB 05 2002

TECH CENTER 1600/2900



SUBMISSION UNDER MPEP 609 D Page 1 of 2	Application Number	09/921,516
	First Named Inventor	ITRI, Loretta
	Attorney Docket Number	ORT-1462

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T2
KAC		<u>Peuckmann</u> et al., "Potential Novel Uses of Thalidomide Focus on Palliative Care", <i>Drugs</i> (2000) 60(2):273-292.	
/		<u>Pronzato</u> et al., "Biochemical Modulation of 5-fluorouracil with Methotrexate in Advanced Colorectal Cancer Patients Pretreated with Adjuvant 5-fluorouracil and Leucovorin", <i>Anticancer Res.</i> (1995) 15(6B):2679-2682.	
/		<u>Tetreault</u> et al., "Treatment of Hairy Cell Leukemia-variant with Cladribine", <i>Leukemia and Lymphoma</i> (1999) 35(3-4):347-354.	
/		E. L. Trimble, "Innovative Therapies for Advanced Ovarian Cancer", <i>Sem. Oncology</i> (2000) 27(3, Supp. 7):24-30.	

Examiner Signature	<i>John G. Canella</i>	Date Considered	9/14/04
-----------------------	------------------------	--------------------	---------